Abstract #0804

Interplay of Choline Metabolites and Genes in Patient-Derived Breast Cancer Xenografts

Maria T. Grinde¹,², Saurabh S. Gorad¹, Nirma Skrbo³,⁴, Siver A. Moestue¹, Einar A. Rdland⁵, Eldrid Borgan¹,⁶, Alexandr Kristian³, Beathe Sitter¹,⁷, Tone Frost Bathen,²⁸, Anne Lise Brresen-Dale⁴,⁶, Gunhild M. Maelandsmo³,⁹, Olav Engebrten⁴,¹⁰, Therese Srlie⁶, Elisabetta Marangoni¹¹, Ingrid Susann Gribbestad,²⁸

¹Dept. of Circulation and Medical Imaging, NTNU, Trondheim, Norway; ²St. Olavs University Hospital, Trondheim, Norway; ³Dept. of Tumor Biology, Institute of Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; ⁴Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ⁵Dept. of Informatics, University of Oslo, Oslo, Norway; ⁶Dept. of Genetics, Oslo University Hospital Radiumhospitalet, Oslo, Norway; ⁷Dept. of Technology, Sr-Trondelag University College, Trondheim, Norway; ⁸Dept. of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; ⁹Dept. of Pharmacy, Faculty of Health Sciences, University of Troms, Troms, Norway; ¹⁰Dept. of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway; ¹¹Preclinical Investigation Unit, Translational Research Department, Institut Curie, Paris, France

We employed high-resolution magic angle spinning (HR MAS) MR spectroscopy and gene expression microarray to map the metabolomic and transcriptomic characteristics related to choline metabolism in large panel of patient-derived breast cancer xenografts (N=34) and to evaluate the clinical relevance of xenograft models for metabolomic studies. The results showed significantly different choline metabolic and gene expression profiles in luminal B and basal-like subtypes of breast cancer. It also indicated that the patient-derived xenografts are representative of human breast cancer, and may be valuable for further exploration of subtype-specific metabolic and transcriptomic traits.